remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year
Champions Oncology, Inc. (Nasdaq:CSBR), a leading translational oncology research organization, today announced its financial results for its second quarter of fiscal 2026, ended October 31, 2025.
Second Quarter and Recent Highlights:
Total revenue increased 11% to $15 million
Oncology services profit of $7.8 million; oncology services margin of 52%
Net income of $237,000
Adjusted EBITDA of $843,000
First Half 2026 Highlights:
Total revenue increased 5% to $29 million
Oncology services profit of $13.8 million; oncology services margin of 47%
Adjusted EBITDA of $962,000
Robert Brainin, CEO of Champions, commented, "Our recent results reinforced our confidence in the Company's ongoing return to growth, as we continued to make progress. While our business can vary period to period, we manage and evaluate performance primarily on an annual basis and remain focused on delivering sustainable year-over-year revenue growth. We continue to be cautiously optimistic that the pharma and biotech funding environment is beginning to strengthen, which should support improved bookings as we move into calendar 2026."
"In parallel with our core services business, we continued to invest in our data platform-expanding its capabilities to provide greater value to our pharma partners-and strengthened our business development organization to support adoption of these offerings. As our data business scales, we expect it to contribute meaningfully to long-term growth, even as it introduces additional variability in shorter reporting periods. Together, these growth engines position Champions to create meaningful long-term value for our shareholders."
David Miller, CFO of Champions, added, "From a financial standpoint, the period reflected continued progress in our operating model. Oncology services margin improved as higher revenue was generated on a largely stable cost base, highlighting the leverage in our business as volumes increase. Operating expenses rose as planned, reflecting targeted investments in areas that support future growth, particularly within our data platform and related infrastructure."
"Based on our year-to-date performance and current visibility, we remain on track to deliver year-over-year revenue growth and to achieve positive adjusted EBITDA for the full fiscal year. We believe the combination of disciplined cost control and targeted strategic investment positions the Company for continued improvement as market conditions strengthen."
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.